Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 11 Breast Neoplasms 8 Prostatic Neoplasms 7 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Melanoma 5 COVID-19 4 Multiple Myeloma 3 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumor 2 Recurrence 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasm Metastasis 2 Leukemia 2 Glioblastoma 2 Cholangiocarcinoma 2 Adenocarcinoma of Lung 2 Adenocarcinoma 2 Urologic Diseases 1 Untreated Resectable Pancreatic Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1

Interventions

Cyclophosphamide 22 blinatumomab 18 Cytarabine 15 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Lenalidomide 7 Dexamethasone 7 Methotrexate 6 Daunorubicin 6 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Melphalan 4 Idarubicin 4 Etoposide 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Maintenance 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Cladribine 3 Asparaginase 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × Hydroxychloroquine × Clear all

NCT04841148 2026-04-09

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡